MA40921A - Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation - Google Patents

Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation

Info

Publication number: MA40921A
Authority: MA; Morocco
Prior art keywords: chemerical; cldn; receptors; genetic; methods
Prior art date: 2014-11-05

Application number

MA040921A

Other languages

English (en)

Inventor

Scott J Dylla

Paul Anthony Escarpe

David Liu

Robert A Stull

Original Assignee

Abbvie Stemcentrx Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-11-05

Filing date

2015-11-03

Publication date

2017-09-12

2014-11-05 Priority claimed from PCT/US2014/064165 external-priority patent/WO2015069794A2/fr

2015-11-03 Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc

2017-09-12 Publication of MA40921A publication Critical patent/MA40921A/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Zoology (AREA)
Cell Biology (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Wood Science & Technology (AREA)
Toxicology (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Epidemiology (AREA)
General Engineering & Computer Science (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Microbiology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

MA040921A 2014-11-05 2015-11-03 Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation MA40921A (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/US2014/064165 WO2015069794A2 (fr)	2013-11-06	2014-11-05	Nouveaux anticorps anti-claudine et leurs méthodes d'utilisation
US201562157928P	2015-05-06	2015-05-06
US201562247108P	2015-10-27	2015-10-27

Publications (1)

Publication Number	Publication Date
MA40921A true MA40921A (fr)	2017-09-12

Family

ID=55909771

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA040921A MA40921A (fr)	2014-11-05	2015-11-03	Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation

Country Status (23)

Country	Link
US (1)	US20170334991A1 (fr)
EP (1)	EP3215523A4 (fr)
JP (1)	JP2017535283A (fr)
KR (1)	KR20170085531A (fr)
CN (1)	CN107207580A (fr)
AU (1)	AU2015343079A1 (fr)
BR (1)	BR112017009517A2 (fr)
CA (1)	CA2966618A1 (fr)
CL (1)	CL2017001118A1 (fr)
CO (1)	CO2017005538A2 (fr)
CR (1)	CR20170235A (fr)
DO (1)	DOP2017000110A (fr)
EA (1)	EA201790967A1 (fr)
EC (1)	ECSP17031725A (fr)
IL (1)	IL252090A0 (fr)
MA (1)	MA40921A (fr)
MX (1)	MX2017005797A (fr)
PE (1)	PE20171060A1 (fr)
PH (1)	PH12017500825A1 (fr)
SG (1)	SG11201703669YA (fr)
TW (1)	TW201625677A (fr)
WO (1)	WO2016073649A1 (fr)
ZA (1)	ZA201703471B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ595212A (en)	2009-03-30	2014-02-28	Eisai R&D Man Co Ltd	Liposome composition
SG11201603397QA (en) *	2013-11-06	2016-05-30	Stemcentrx Inc	Novel anti-claudin antibodies and methods of use
ES2952680T3 (es)	2016-04-28	2023-11-03	Eisai R&D Man Co Ltd	Eribulina para inhibir el crecimiento tumoral
BR112019007145A2 (pt) *	2016-10-14	2019-07-02	Eisai R&D Man Co Ltd	combinação de um antagonista de pd-1 e eribulina para o tratamento de câncer urotelial
EP3690038A4 (fr)	2017-09-29	2021-05-19	Daiichi Sankyo Company, Limited	Conjugué anticorps-dérivé de pyrrolobenzodiazépine
WO2020051562A2 (fr)	2018-09-07	2020-03-12	Beam Therapeutics Inc.	Compositions et procédés d'amélioration de l'édition de base
CA3112011A1 (fr)	2018-09-07	2020-03-12	Beam Therapeutics Inc.	Compositions et procedes d'administration d'un systeme d'edition de nucleobase
EP3892333A4 (fr) *	2018-12-07	2022-11-30	CRAGE medical Co., Limited	Polyimmunothérapie anti-tumorale
JP2022524906A (ja) *	2019-01-07	2022-05-11	クレージュメディカルカンパニー，リミテッド	細胞免疫療法の組み合わせ
SG11202108339TA (en) *	2019-02-08	2021-08-30	Biontech Cell & Gene Therapies Gmbh	Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancers
WO2020205759A1 (fr) *	2019-03-29	2020-10-08	Pact Pharma, Inc.	Thérapies cellulaires adoptives personnalisées spécifiques à un néo-antigène
US12415853B2 (en)	2019-05-16	2025-09-16	Qilu Pharmaceutical Co., Ltd.	Antibody against claudin 18A2 and use thereof
US12036204B2 (en)	2019-07-26	2024-07-16	Eisai R&D Management Co., Ltd.	Pharmaceutical composition for treating tumor
WO2021129927A1 (fr) *	2019-12-23	2021-07-01	Biontech Cell & Gene Therapies Gmbh	Traitement avec des cellules effectrices immunitaires modifiées pour exprimer un récepteur d'antigène
CN113637082A (zh) *	2020-04-27	2021-11-12	启愈生物技术(上海)有限公司	一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用
US20210347847A1 (en) *	2020-05-11	2021-11-11	The Broad Institute, Inc.	Therapeutic targeting of malignant cells using tumor markers
TW202241935A (zh)	2020-12-18	2022-11-01	美商世紀治療股份有限公司	具有可調適受體專一性之嵌合抗原受體系統
KR20230154317A (ko) *	2021-03-05	2023-11-07	상하이 젠베이스 바이오테크놀로지 씨오., 엘티디.	항-cldn6 항체 및 이의 용도
CN114478802B (zh) *	2022-01-28	2023-05-26	郑州大学	一种嵌合抗原受体及其应用
CN115991770A (zh) *	2022-05-11	2023-04-21	迈威(上海)生物科技股份有限公司	抗人gas6抗体或其抗原结合片段及其应用
WO2024088325A1 (fr) *	2022-10-25	2024-05-02	科济生物医药（上海）有限公司	Anticorps et son utilisation
CN117169518B (zh) *	2023-11-03	2024-01-19	赛德特(北京)生物工程有限公司	T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒
WO2025209525A1 (fr) *	2024-04-03	2025-10-09	江苏恒瑞医药股份有限公司	Anticorps anti-cldn6, conjugué anticorps-médicament le comprenant et utilisation médicale associée

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101074261A (zh) *	2006-04-30	2007-11-21	北京同为时代生物技术有限公司	Trail受体1和/或trail受体2特异性抗体及其应用
CN101951953A (zh) *	2007-02-27	2011-01-19	株式会社未来创药研究所	含抗grp78抗体作为有效成分的药物组合物
EP2241578B1 (fr) *	2008-01-11	2016-04-20	The University of Tokyo	Anticorps anti-cldn6
NZ734307A (en) *	2009-11-11	2020-05-29	Ganymed Pharmaceuticals Ag	Antibodies specific for claudin 6 (cldn6)
EP2404936A1 (fr) *	2010-07-06	2012-01-11	Ganymed Pharmaceuticals AG	Thérapie du cancer utilisant des anticorps in vivo dirigés sur la cible CLDN6
ES2769574T3 (es) *	2013-03-15	2020-06-26	Michael C Milone	Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
SG11201603397QA (en) *	2013-11-06	2016-05-30	Stemcentrx Inc	Novel anti-claudin antibodies and methods of use
ME03407B (fr) *	2014-04-01	2020-01-20	Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh	Immunorécepteurs et épitopes de lymphocytes t spécifiques de la claudine-6
WO2016180467A1 (fr) *	2015-05-11	2016-11-17	Biontech Cell & Gene Therapies Gmbh	Renforcement de l'effet de lymphocytes t génétiquement modifiés par car, par vaccination par acide nucléique
SG11201804673WA (en) *	2015-12-04	2018-06-28	Abbvie Stemcentrx Llc	Novel anti-claudin antibodies and methods of use

2015
- 2015-11-03 MA MA040921A patent/MA40921A/fr unknown
- 2015-11-04 US US15/524,675 patent/US20170334991A1/en not_active Abandoned
- 2015-11-04 BR BR112017009517A patent/BR112017009517A2/pt not_active Application Discontinuation
- 2015-11-04 MX MX2017005797A patent/MX2017005797A/es unknown
- 2015-11-04 CR CR20170235A patent/CR20170235A/es unknown
- 2015-11-04 EP EP15857690.0A patent/EP3215523A4/fr not_active Withdrawn
- 2015-11-04 WO PCT/US2015/059106 patent/WO2016073649A1/fr not_active Ceased
- 2015-11-04 EA EA201790967A patent/EA201790967A1/ru unknown
- 2015-11-04 AU AU2015343079A patent/AU2015343079A1/en not_active Abandoned
- 2015-11-04 CA CA2966618A patent/CA2966618A1/fr not_active Abandoned
- 2015-11-04 CN CN201580072018.5A patent/CN107207580A/zh active Pending
- 2015-11-04 JP JP2017543306A patent/JP2017535283A/ja active Pending
- 2015-11-04 PE PE2017000813A patent/PE20171060A1/es not_active Application Discontinuation
- 2015-11-04 SG SG11201703669YA patent/SG11201703669YA/en unknown
- 2015-11-04 KR KR1020177015413A patent/KR20170085531A/ko not_active Withdrawn
- 2015-11-05 TW TW104136552A patent/TW201625677A/zh unknown
2017
- 2017-05-02 DO DO2017000110A patent/DOP2017000110A/es unknown
- 2017-05-03 IL IL252090A patent/IL252090A0/en unknown
- 2017-05-04 PH PH12017500825A patent/PH12017500825A1/en unknown
- 2017-05-05 CL CL2017001118A patent/CL2017001118A1/es unknown
- 2017-05-19 ZA ZA2017/03471A patent/ZA201703471B/en unknown
- 2017-05-25 EC ECIEPI201731725A patent/ECSP17031725A/es unknown
- 2017-06-02 CO CONC2017/0005538A patent/CO2017005538A2/es unknown

Also Published As

Publication number	Publication date
BR112017009517A2 (pt)	2017-12-19
PH12017500825A1 (en)	2017-10-18
WO2016073649A1 (fr)	2016-05-12
US20170334991A1 (en)	2017-11-23
ZA201703471B (en)	2019-06-26
EP3215523A1 (fr)	2017-09-13
AU2015343079A1 (en)	2017-05-25
DOP2017000110A (es)	2017-05-31
SG11201703669YA (en)	2017-06-29
CR20170235A (es)	2017-07-21
CA2966618A1 (fr)	2016-05-12
TW201625677A (zh)	2016-07-16
EA201790967A1 (ru)	2017-10-31
EP3215523A4 (fr)	2018-06-20
CL2017001118A1 (es)	2018-01-05
MX2017005797A (es)	2017-10-23
CN107207580A (zh)	2017-09-26
IL252090A0 (en)	2017-07-31
CO2017005538A2 (es)	2017-10-10
KR20170085531A (ko)	2017-07-24
PE20171060A1 (es)	2017-07-21
JP2017535283A (ja)	2017-11-30
ECSP17031725A (es)	2017-06-30

Publication	Publication Date	Title
FR23C1004I2 (fr)	2024-01-05	Antagonistes du fcrn et procédés d'utilisation
MA40921A (fr)	2017-09-12	Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
EP3436030A4 (fr)	2019-11-06	Récepteurs chimériques et leurs procédés d'utilisation
EP3394065A4 (fr)	2019-07-10	Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés
EP3303435A4 (fr)	2019-02-20	Hydrofluoroléfines et procédés d'utilisation associés
MA51552A (fr)	2021-03-24	Anticorps anti-ox40 et procédés d'utilisation
EP3377612A4 (fr)	2019-07-24	Expression fonctionnelle de monooxygénases et procédés d'utilisation
IL251970B (en)	2021-12-01	Anti-cd79b antibodies and methods of use
IL251972B (en)	2022-03-01	Analyzing and utilizing landscapes
IL254039A0 (en)	2017-10-31	Anti-pvrig antibodies and methods of use
EP3436048A4 (fr)	2019-11-27	Néoantigènes et leurs procédés d'utilisation
PL3353210T3 (pl)	2025-02-24	Przeciwciała anty-TIGIT i sposoby stosowania
EP3119761C0 (fr)	2023-06-07	Agents ciblant les amyloïdes et procédés de leur utilisation
EP3350508A4 (fr)	2019-05-22	Lucarne artificielle et procédés
MA47849A (fr)	2020-01-29	Anticorps anti-gitr et leurs procédés d'utilisation
MA43018A (fr)	2021-06-02	Anticorps anti-pd1 et procédés d'utilisation
EP2971000A4 (fr)	2016-11-23	Polypeptides phi-4 et leurs procédés d'utilisation
DK3149042T3 (da)	2019-11-04	PD-L1-antistoffer og anvendelser deraf
MA55097A (fr)	2022-01-05	Oxystérols et leurs procédés d'utilisation
EP2986623A4 (fr)	2016-09-28	19-nor-c21-n-pyrazolyl-stéroïdes c3,3-disubstitués et procédés d'utilisation de ceux-ci
EP2970156A4 (fr)	2016-08-17	Benzoxazoles substitués et leurs procédés d'utilisation
EP3319610A4 (fr)	2019-03-06	Oxystérols et leurs procédés d'utilisation
EP3319612A4 (fr)	2019-03-06	Oxystérols et leurs procédés d'utilisation
EP3635000A4 (fr)	2021-04-14	Manabodies et procédés d'utilisation
EP3302558A4 (fr)	2019-01-16	Agents anticancéreux et procédés d'utilisation